Microchips’ innovative drug delivery technology is designed to store and precisely deliver hundreds of therapeutic doses over months or years in a single implant. The implant is intended to be operated by the patient to deliver medication on demand or on a pre-determined schedule that can be activated or deactivated wirelessly, as required.

With the support of the The Bill & Melinda Gates Foundation in the form of approximately $17.9 million in grant funding to date, and the potential for up to an additional $2.5 million in grant funding in 2020, Microchips has been developing an implantable long-acting, reversible contraceptive application of the technology.

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

The addition of this new contraceptive technology builds upon a diverse portfolio of products for women’s health, which includes a novel, monthly, hormone-free contraceptive, Ovaprene, and uniquely positions Daré as a leader in contraceptive innovation with two potentially first-in-class products in development.

For more information, view the press release.